Drug Establishment License (DEL)
A DEL (Drug Establishment License) governed by Part C, Division 1A of the Food and Drug Regulations—is a mandatory license for any business in Canada involved in fabricating, packaging/labeling, testing, importing, distributing, or wholesaling human or veterinary drugs. “Applicable drugs”- This includes pharmaceutical drugs, APIs, vaccines, biologics, radiopharmaceuticals, narcotics, and cannabis-derived drugs. Regulatory impact- No licensable activity may perform without a valid DEL
- Those operating under a suspended or canceled DEL must cease all licensable actions.
- Fabricate: Prepare or preserve a drug for sale.
- Package/label: Place drugs in containers or apply labels
- Test: Conduct required quality control testing
- Import: Bring drugs into Canada for sale
- Distribute/wholesale: Sell drugs for resale (non-retail)
- New DEL Application (C.01A.005): First-time applications or reactivation after cancellation
- Amendment Application (C.01A.006): To add/remove buildings, activities, drug categories, sterile product status, or update annexes
- Annual License Review (ALR, C.01A.009): Due annually before April 1; necessary even for new licenses issued near that date
- NERBY (“New Evidence Required By”): A conditional form allowing license renewal with a commitment to provide GMP evidence by a set date
- Reinstatement (C.01A.018): To resume activities after a suspension–subject to inspection. Note: if suspended >12 months, license is automatically canceled
- Cancellation: Voluntarily request license cancellation via letter or email.
- Company info – legal name, contact person, emergency contact details.
- Domestic building(s) – address, defined activities (fabrication, etc.), drug category, dosage forms, and whether sterile operations occur.
- Importers – detailed annexes listing foreign buildings, their activities, and alignment with Canadian import scope
- Drug details – list of APIs, dosage forms, any controlled or narcotic substances.
- GMP evidence – required for fabricators, importers, and foreign sites. Can incorporate previous inspection reports or certificates, especially under Mutual Recognition Agreements.
- Applicant Information
- Canadian Building Information
- Foreign Building Information
- amend the Active Pharmaceutical Ingredient (API) Foreign Building annex of your DEL
- add an API Foreign Building Annex to your DEL or
- add an API Foreign Building Annex as part of a New DEL application
- Licensees may request NERBY, delaying GMP evidence submission to a future deadline while maintaining the license.
- Missing ALR or NERBY deadlines can trigger suspension or final cancellation.
- It does not require Form FRM-0033.
- Suspension – for GMP breaches, non-disclosure of major facts, or public health risks.
- Cancellation – if:
- Suspended for >12 months,
- Fail to file ALR by April 1,
- Do not respond to deficiency notices within prescribed timeline
Why Partner with Masuu Global Solutions?
At Masuu Global Solutions, we specialize in guiding pharmaceutical and biotech firms through the DEL. Navigating the complex and highly regulated process of obtaining and maintaining a Drug Establishment Licence (DEL) in Canada can be overwhelming—especially for growing pharmaceutical, biotech, and healthcare companies. At Masuu Global Solutions, we don’t just offer guidance—we become your strategic partner through every step of the DEL journey.
Strategic Application Planning We work closely with your team to build a strong application from the ground up, ensuring that all your buildings, activities, dosage forms, and drug categories are clearly defined and aligned with Health Canada’s requirements. Whether you’re applying for the first time or amending an existing licence, we streamline the process and eliminate guesswork. GMP Documentation & Evidence Support Compiling Good Manufacturing Practices (GMP) evidence can be one of the most time-consuming parts of a DEL submission. We simplify it. Our regulatory experts prepare complete, audit-ready dossiers that meet Health Canada’s expectations—reducing the risk of deficiency notices and speeding up approvals. Foreign Annex Management If you’re importing drugs or APIs from outside Canada, each foreign site must be listed and verified. We manage your Foreign Building Annexes end-to-end: from collecting proper GMP documentation and inspection reports to formatting them according to Canadian regulatory standards. You stay compliant across borders—without the hassle. Ongoing Support: ALRs, Renewals & NERBY
-
We provide end-to-end lifecycle support, including:
- Annual License Review (ALR) preparation and submission
- NERBY (New Evidence Required By) scheduling and documentation
- Updates and amendments as your operations evolve
- Quick action in response to inspection outcomes or scope changes
Frequently Asked Questions
A Drug Establishment License (DEL), governed by Part C, Division 1A of the Food and Drug Regulations, is required for businesses conducting regulated drug activities in Canada. These activities can include fabricating, packaging/labeling, testing, importing, distributing, or wholesaling human or veterinary drugs.
A DEL is generally required when a company fabricates, packages or labels, tests, imports, distributes, or wholesales applicable drugs in Canada. This can cover pharmaceutical drugs, APIs, vaccines, biologics, radiopharmaceuticals, narcotics, and cannabis-derived drugs, subject to applicable requirements and exemptions.
Companies cannot generally perform licensable activities without a valid DEL. If a DEL is suspended or cancelled, the establishment must cease the activities covered by the licence until the applicable regulatory requirements for reinstatement or re-licensing are met.
Health Canada provides different application pathways, including New DEL Applications, Amendments, Annual Licence Reviews (ALR), NERBY requests, Reinstatement, and Cancellation. Amendments can be used to add or remove buildings, activities, drug categories, sterile operations, or applicable annex information.
A DEL application generally includes company and contact information, Canadian building details, activities, drug categories, dosage forms, sterile operations, and applicable foreign building information. Importers may also need to provide foreign site details and relevant GMP evidence.
FRM-0033 is the prescribed form used for DEL applications and includes applicant, Canadian building, and foreign building information. A Table A annex is additionally required when adding or amending an API Foreign Building Annex, including certain new DEL applications involving foreign API sites.
The Annual Licence Review (ALR) is a yearly requirement for active DEL holders to keep their licence current and valid. It must be completed within the applicable Health Canada timeline, and the provided requirements specify April 1 as the annual deadline; ALR submissions do not require Form FRM-0033.
NERBY (New Evidence Required By) is a mechanism that allows a DEL holder to provide required GMP evidence by a specified future date while maintaining the licence, where applicable. Missing the NERBY or other regulatory deadlines can lead to enforcement actions, including suspension or cancellation.
Health Canada may suspend a DEL because of GMP deficiencies, failure to disclose significant information, or risks to public health. A licence may be cancelled in circumstances such as remaining suspended for more than 12 months, failing to complete required ALR obligations, or not responding to deficiency notices within the prescribed timeframe.
Masuu Global provides end-to-end DEL support, including application planning, GMP documentation and evidence preparation, foreign building annex management, amendments, ALRs, NERBY support, and lifecycle updates. Our team helps ensure buildings, activities, dosage forms, drug categories, and foreign sites are appropriately documented and aligned with Health Canada requirements.
